NantHealth Inc (NYSE:NH) has been given an average rating of “Buy” by the six analysts that are currently covering the firm. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $18.00.

A number of analysts have recently commented on NH shares. Zacks Investment Research downgraded NantHealth from a “hold” rating to a “sell” rating in a research note on Wednesday, September 14th. Canaccord Genuity restated a “buy” rating and issued a $17.00 target price on shares of NantHealth in a research note on Monday, September 19th. FBR & Co restated a “buy” rating on shares of NantHealth in a research note on Wednesday, August 10th. Cowen and Company started coverage on NantHealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, Jefferies Group started coverage on NantHealth in a research note on Monday, June 27th. They issued a “buy” rating on the stock.

A number of institutional investors have recently modified their holdings of the company. FMR LLC acquired a new position in shares of NantHealth during the second quarter worth about $11,250,000. Blackstone Group L.P. purchased a new position in shares of NantHealth during the second quarter worth approximately $7,463,000. Jefferies Group LLC purchased a new position in shares of NantHealth during the second quarter worth approximately $6,943,000. Finally, Wildcat Capital Management LLC purchased a new position in shares of NantHealth during the second quarter worth approximately $3,008,000.

Shares of NantHealth (NYSE:NH) opened at 13.41 on Wednesday. NantHealth has a 1-year low of $9.79 and a 1-year high of $16.63. The company’s market cap is $1.63 billion. The firm has a 50-day moving average price of $13.11 and a 200-day moving average price of $12.67.

NantHealth (NYSE:NH) last issued its earnings results on Tuesday, August 9th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.26. The company earned $31.50 million during the quarter, compared to analysts’ expectations of $23.55 million. The business’s revenue for the quarter was up 166.9% compared to the same quarter last year. On average, equities analysts expect that NantHealth will post ($0.59) EPS for the current year.

NantHealth Company Profile

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

5 Day Chart for NYSE:NH

Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.